

Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028

<https://marketpublishers.com/r/G3C83BD1BE99EN.html>

Date: November 2022

Pages: 0

Price: US\$ 3,000.00 (Single User License)

ID: G3C83BD1BE99EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028 Report Overview:

Global Oncolytic Virus Immunotherapy Therapy Market Overview

Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1 Billion By 2028

Insight On More Than 180 Oncolytic Virus Immunotherapies In Clinical Trials

Patent Information On More Than 60 Therapies in Clinical Trials

IMLYGIC, Oncorine, Delytact: Availability, Dosage & Price Analysis

Oncolytic Virus Immunotherapy Clinical Pipeline By Country, Phase, Indication, Organization, Patient Segment

Oncolytic Virus Immunotherapy Application By 10 Cancer

Recent Strategic Partnerships, Collaborations, Mergers & Acquisitions

Global cancer immunotherapy market encompasses broad range of applications, in which oncolytic virus immunotherapy is playing a vital role in the overall development.

The therapy involves a very basic thread of using virus for targeting cancer cells and to harness the natural as well as destructive power of the immune system against the cancer cells. In a very short period of time, the clinical outcome associated with the therapy has laid down foundation for the over-achieving future of the therapy. The therapy market is estimated to get recognized as a necessity in the overall cancer therapeutics market where old and traditional therapies available are not successful in declining the increasing mortality rate across the globe.

Researchers have been successful in modifying the basic immunotherapy strategy by introducing the benefits of virus in targeting the host cells. Beyond the excellent capacity of the virus to get incorporated into the host cell, the therapeutic introduction of virus in the cancer therapeutics is providing enormous amounts of opportunities which were somehow lacking in the overall cancer therapeutics market for prolonged period of time. The future approval of the oncolytic virus therapy against wide range of cancer types is believed to strengthen the pharmaceutical industry to reach the revenue sales that have not been recorded for any of the cancer therapy drugs.

The strong link of the therapy with clinical pipeline and the future timeframe which is about to justify the applications of the therapy are observed to over-come the challenges which the researchers have been facing in terms of resistance development, off-targeting and adverse side effects. Amid the growth of other cancer therapies in the cancer therapeutics market, oncolytic virus therapy soon is going to deliver significant revolution and growth. The unimaginable applications of the therapy and the orientation of the government bodies towards expanding the clinical trial market of the same is estimated to develop the market as a dominant one for millions of patients who haven't received any benefits from the available therapies. The entry of the oncolytic virus therapy into the market horizon is estimated to provide enormous healthcare opportunities to the patients who have been struggling with cancer for a prolonged period of time.

As per Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028 report findings, the overall appreciation that the therapy has achieved in such shorter time period is poised to incline the therapy towards substantial growth. In the coming time period, the therapy market is believed to deliver promising trends and opportunities for the researchers working in different bio-pharmaceutical companies and research centers, with hundreds of driving forces driving the market through various complications. On the regulatory side, the legislations of developed pharmaceutical countries are also inclining towards boosting the researchers to expand the market applications and drive the competition in the right direction, where appropriate funds for

the clinical research activities is acting as the catalyst for the therapy. The unlimited applications found within the therapy and the clinical platform for the same is estimated to move the therapy towards success at an unprecedented rate in the coming years.

Contents

1. INTRODUCTION TO ONCOLYTIC VIRUS: TRAIL FROM GENESIS TO BIOGENETICS

2. PRIMER OF VIROTHERAPY IN MALIGNANCIES

- 2.1 Oncolytic Viruses Towards Cancer
- 2.2 Approaches for Targeting Tumor Cells
- 2.3 Viral Oncolysis Mechanism of Action

3. ONCOLYTIC VIRUSES IMMUNOTHERAPY OVERVIEW

- 3.1 Stimulation of Antitumor Immune Responses
- 3.2 Oncolytic Viruses as Cancer Vaccines

4. POTENTIAL ONCOLYTIC VIRUS IMMUNOTHERAPY FOR CANCERS

- 4.1 Breast Cancer
- 4.2 Lung Cancer
- 4.3 Prostate Cancer
- 4.4 Melanoma
- 4.5 Brain Tumor
- 4.6 Blood Cancer
- 4.7 Colorectal Cancer
- 4.8 Bladder Cancer
- 4.9 Pancreatic Cancer
- 4.10 Head & Neck Cancer

5. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY THERAPY MARKET OVERVIEW

- 5.1 Preface Towards Oncolytic Virus Arcade
- 5.2 Market Aspects of Approved Oncolytic Viruses

6. IMLYGIC (TALIMOGENE LAHERPAREPVEC): CLINICAL & PRICING INSIGHT

- 6.1 Clinical Overview
- 6.2 Availability, Dosage & Price Analysis

7. ONCORINE (H101): CLINICAL & PRICING INSIGHT

7.1 Clinical Overview

7.2 Availability, Dosage & Price Analysis

8. DELYTACT (DS 1647): CLINICAL & PRICING INSIGHT

8.1 Clinical Overview

8.2 Availability, Dosage & Price Analysis

9. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY CLINICAL PIPELINE OVERVIEW

9.1 By Phase

9.2 By Company

9.3 By Country

9.4 By Indication

9.5 By Patient Segment

10. GLOBAL ONCOLYTIC VIRUSES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

10.1 Research

10.2 Preclinical

10.3 Phase-I

10.4 Phase-I/II

10.5 Phase-II

10.6 Phase-III

10.7 Registered

11. STRATEGIC PARTNERSHIPS, COLLABORATIONS, MERGERS & ACQUISITIONS TO ADVANCE THE ONCOLYTIC VIRUS THERAPY MARKET

11.1 Estrella Biopharma Signs Deal To Merge With Blank Check Company

11.2 ABL & Imugene Announce Partnership to Advance Oncolytic Virus Candidates Into Late Clinical Trial Phase

11.3 TILT Biotherapeutics & Merck to Undergo Clinical Trial Collaboration for Refractory Non-Small Cell Lung Cancer

11.4 Virogin Biotech & MD Anderson Announce Strategic Collaboration For Treating Advance Cancers

11.5 ABL Signs Pact With KaliVir On Oncolytic Viruses

11.6 Targovax Announces Clinical Collaboration With Agenus For Melanoma Trial

11.7 KaliVir Announces Exclusive Agreement With Roche For Developing Novel Oncolytic Viruses

11.8 ImmVira & Roche Enter Cooperation Agreement For Evaluating Novel Combination For Cancer Therapy

11.9 Calidi & Edoc Agree On Merger To Revolutionize Oncolytic Viral Therapies

11.10 Synthetic Biologics Completes Acquisition of VCN Biosciences

11.11 VacV Biotherapeutics Exits Stealth With \$3 Million Investment

11.12 Targovax Enters Research Collaboration With Karolinska Institutet Professor

11.13 Transgene and PersonGen To Collaborate To Evaluate New Combination Therapy Against Solid Tumors

11.14 Lokon Pharma Initiates Collaboration With To Develop Novel Cancer Therapeutics

11.15 Bionaut Labs and Candel Therapeutics Announce Collaboration For Novel Targeting Mechanism For Oncolytic Virus Delivery

11.16 Imugene & Eureka Announce Strategic Collaboration to Accelerate Oncolytic Virus and T-Cell Therapy Combination

11.17 CG Oncology Enters Into Clinical Trial Collaboration With Roche For Novel Oncolytic Immunotherapy Combination

11.18 Imugene Enters Into Exclusive Strategic Partnership With Celularity To Develop Novel Combination For Treating Solid Tumors

12. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET DYNAMICS

12.1 Favorable Market Parameters

12.2 Growth Inhibitors

13. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET FUTURE OUTLOOK

14. COMPETITIVE LANDSCAPE

14.1 AdCure Bio

14.2 Beijing SyngenTech

14.3 BioVex Inc.

14.4 Calidi Biotherapeutics

14.5 Genelux Corporation

- 14.6 Immvira Pharma
- 14.7 Jennerex Biotherapeutics
- 14.8 KaliVir
- 14.9 Lokon Pharma
- 14.10 Merck
- 14.11 Oncolys BioPharma
- 14.12 Oncorus
- 14.13 PsiOxus Therapeutics
- 14.14 Seneca Therapeutics
- 14.15 Shanghai Sunway Biotech
- 14.16 Takara Bio
- 14.17 Targovax
- 14.18 TILT Biotherapeutics
- 14.19 Transgene
- 14.20 Virogin Biotech

List Of Figures

LIST OF FIGURES

- Figure 1-1: Demonstration of Categorization of Oncolytic Viruses
- Figure 1-2: Illustration of Major Events in Clinical Virotherapy
- Figure 2-1: Potential Advantages of Oncolytic Viruses over Conventional Therapies
- Figure 2-2: The Diagrammatic Representation of Entry of Virions into Cancerous cells
- Figure 2-3: Route of Anti-tumoral Efficacy of Oncolytic Viruses
- Figure 2-4: Mechanism of Tumor Destruction by Oncolytic Viruses
- Figure 2-5: Categorization Followed by Oncolytic Viruses for Tumor Selectivity
- Figure 3-1: Demonstration of Phases of Immune Responses Elicited by the Oncolytic Viruses
- Figure 3 2: Categorization of Oncolytic Viruses over the Basis of their Behavior
- Figure 3 3: Diagrammatic Representation of Oncolysis Shown by Reovirus
- Figure 3 4: Mechanism of Oncolytic Behavior of Adenoviruses
- Figure 4-1: Selectively Killing of Prostate Cancer Cells by Oncolytic M-Protein Strains of VSV
- Figure 4-2: Proposed Treatment of Oncolytic Viruses for Hematological Malignancies
- Figure 5-1: Global - Oncolytic Virus Immunotherapy Market Opportunity (US\$ Million), 2021 -2028
- Figure 6-1: Imlygic – US Patent Expiration Year
- Figure 6-2: Imlygic – Price of 1 Million PUF/ml & 100 Million PUF/ml Injectable Suspension (US\$), November'2022
- Figure 6-3: Imlygic – Dose for Initial Treatment Cycle & Subsequent Treatment Cycle (Million PFU/ ml), November'2022
- Figure 6-4: Imlygic – Duration of Initial & Subsequent Treatment Cycle (weeks), November'2022
- Figure 6-5: Imlygic – Average Price of Initial Treatment Cycle & Each Subsequent Treatment Cycle (US\$), November'2022
- Figure 6-6: Imlygic – Volume Administered by Size of Lesion (ml), November'2022
- Figure 7-1: Oncorine - Cost of Single Dose & Single Treatment Course (US\$), September'2020
- Figure 7-2: Oncorine – Duration of Treatment Cycle by Type of Cancer (Days), November'2022
- Figure 8-1: Delytact – Initial & Present Price (US\$), November'2022
- Figure 8-2: Delytact - Designations
- Figure 8-3: Japan – Malignant Gliomas Incidences, 2022-2026
- Figure 9-1: Oncolytic Virus Immunotherapy Clinical Trials by Phase (Numbers), 2022 till

2028

Figure 9-2: Global - Oncolytic Virus Immunotherapy Clinical Trials by Company (Numbers), 2022 till 2028

Figure 9-3: Global - Oncolytic Virus Immunotherapy Clinical Trials by Country (Numbers), 2022 till 2028

Figure 9-4: Global - Oncolytic Virus Immunotherapy Clinical Trials by Indication (Numbers), 2022 till 2028

Figure 9-5: Global - Oncolytic Virus Immunotherapy Clinical Trials by Patient Segment (Numbers), 2022 till 2028

Figure 12-1: Major Drivers for the Oncolytic Virus Therapies

Figure 12-2: Major Challenges Faced by Oncolytic Viral Therapies

I would like to order

Product name: Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/G3C83BD1BE99EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3C83BD1BE99EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970